Oryzon Announces Topline Results from Phase IIb PORTICO study of Vafidemstat in Borderline Personality Disorder (BPD)

Results across all efficacy endpoints consistently favored vafidemstat over placebo. Global Statistical Test (GST p-values) confirms consistent trend across efficacy endpoints The primary endpoints, improvement in Borderline Personality Disorder...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials